Coxsackievirus B3 used as a gene therapy vector to express functional FGF2

Gene Therapy

Volumn 19, Issue 12, 2012, Pages 1159-1165

  Kim, D S ^a   Kim, H ^b   Shim, S H ^a   Kim, C ^b   Song, M ^b   Kim, Y H ^b   Jung, Y W ^c   Nam, J H ^a  

^a The Catholic University of Korea   (South Korea)

^b Hanyang University   (South Korea)

^c CHA University   (South Korea)

Author keywords

coxsackievirus B3; human fibroblast growth factor 2; viral vector

Indexed keywords

COMPLEMENTARY DNA; RECOMBINANT FIBROBLAST GROWTH FACTOR; RECOMBINANT FIBROBLAST GROWTH FACTOR 2; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; COXSACKIE VIRUS B3; DRUG EFFICACY; FEMALE; GANGRENE; GENE EXPRESSION; GENE INSERTION; HEART MUSCLE CELL; HELA CELL; HINDLIMB; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIMB BLOOD FLOW; LIMB ISCHEMIA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS RECOMBINANT; VIRUS VIRULENCE;

ANIMALS; ENTEROVIRUS B, HUMAN; FIBROBLAST GROWTH FACTOR 2; GENETIC THERAPY; GENETIC VECTORS; HELA CELLS; HINDLIMB; HUMANS; ISCHEMIA; MICE; MYOCYTES, CARDIAC; REGIONAL BLOOD FLOW; VIRULENCE;

COXSACKIEVIRUS; MUS;

EID: 84870795716     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.201     Document Type: Article

References (37)

1. Tomar RS, Matta H, Chaudhary PM. Use of adeno-associated viral vector fordelivery of small interfering RNA. Oncogene 2003; 22: 5712-5715.
2. Lundstrom K. Latest development in viral vectors for gene therapy. TrendsBiotechnol 2003; 21: 117-122.
3. Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R et al. Genetransfer into humans-immunotherapy of patients with advanced melanoma,using tumor-infiltrating lymphocytes modified by retroviral gene transduction.N Engl J Med 1990; 323: 570-578.
4. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM et al.Cancer regression in patients after transfer of genetically engineered lymphocytes.Science 2006; 314: 126-129.
5. Jiang H, Pierce GF, Ozelo MC, de Paula EV, Vargas JA, Smith P et al. Evidence ofmultiyear factor IX expression by AAV-mediated gene transfer to skeletal musclein an individual with severe hemophilia B. Mol Ther 2006; 14: 452-455.
6. Lyon AR, Sato M, Hajjar RJ, Samulski RJ, Harding SE. Gene therapy: targeting themyocardium. Heart 2008; 94: 89-99.
7. Lehrman S. Virus treatment questioned after gene therapy death. Nature 1999;401: 517-518.
8. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N,Leboulch P et al. LMO2-associated clonal T cell proliferation in two patients aftergene therapy for SCID-X1. Science 2003; 302: 415-419.
9. Bouard D, Alazard-Dany D, Cosset FL. Viral vectors: from virology to transgeneexpression. Br J Pharmacol 2009; 157: 153-165.
10. Segura T, Shea LD. Materials for non-viral gene delivery. Annu Rev Mater Res 2001;31: 25-46.
11. Gardlik R, Palffy R, Hodosy J, Lukacs J, Turna J, Celec P. Vectors and deliverysystems in gene therapy. Med Sci Monit 2005; 11: RA110-RA121.
12. Esfandiarei M, McManus BM. Molecular biology and pathogenesis of viralmyocarditis. Annu Rev Pathol Mech Dis 2008; 3: 125-153.
13. Tu Z, Chapman NM, Hufnagel G, Tracy S, Romero JR, Barry WH et al. Thecardiovirulent phenotype of coxsackievirus B3 is determined at a single site in thegenomic 50 nontranslated region. J Virol 1995; 69: 4607-4618.
14. Chung SK, Kim JY, Kim IB, Park SI, Paek KH, Nam JH. Internalization and traffickingmechanisms of coxsackievirus B3 in HeLa cells. Virology 2005; 333: 31-40.
15. Coyne CB, Bergelson JM. Virus-induced Abl and Fyn kinase signals permitcoxsackievirus entry through epithelial tight junctions. Cell 2006; 124: 119-200.
16. Henke A, Jarasch N, Martin U, Zell R, Wutzler P. Characterization of the protectivecapability of a recombinant coxsackievirus B3 variant expressing interferon-c.Viral Immunol 2008; 21: 38-48.
17. Kim DS, Cho YJ, Kim BG, Lee SH, Nam JH. Systematic analysis of attenuatedCoxsackievirus expressing a foreign gene as a viral vaccine vector. Vaccine 2010;28: 1234-1240.
18. Henke A, Zell R, Ehrlich G, Stelzner A. Expression of immunoregulatory cytokinesby recombinant coxsackievirus B3 variants confers protection against viruscausedmyocarditis. J Virol 2001; 75: 8187-8194.
19. Jeong SY, Ahn JH, Cho YJ, Kim YJ, Kim DS, Jee YM et al. Production of crossreactivepeptide antibodies against viral capsid proteins of human enterovirus Bto apply diagnostic reagent. Microbiol Immunol 2007; 51: 1091-1098.
20. Chung SY, Cho YJ, Kim YJ, Kim DS, Lee HR, Nam JH. Development of peptideantibody against coxsackievirus B3 VP2. J Bacteriol Virol 2006; 36: 109-117.
21. Chappell JC, Song J, Burke CW, Klibanov AL, Price RJ. Targeted delivery ofnanoparticles bearing fibroblast growth factor-2 by ultrasonic microbubbledestruction for therapeutic arteriogenesis. Small 2008; 4: 1769-1777.
22. Lee JS, Kim JM, Kim KL, Jang HS, Shin IS, Jeon ES et al. Combined administration ofnaked DNA vectors encoding VEGF and bFGF enhances tissue perfusion andarteriogenesis in ischemic hindlimb. Biochem Biophys Res Commun 2007; 360:752-758.
23. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E et al. Angiogenicsynergism, vascular stability and improvement of hindlimb ischemia by acombination of PDGF-BB and FGF-2. Nat Med 2003; 9: 604-613.
24. Kim H, Cho HJ, Kim SW, Liu B, Choi YJ, Lee J et al. CD31+ cells represent highlyangiogenic and vasculogenic cells in bone marrow: novel role of nonendothelialCD31+ cells in neovascularization and their therapeutic effects on ischemicvascular disease. Circ Res 2010; 107: 602-614.
25. Kim SW, Kim H, Cho HJ, Lee JU, Levit R, Yoon YS. Human peripheral blood-derivedCD31+ cells have robust angiogenic and vasculogenic properties and are effectivefor treating ischemic vascular disease. J Am Coll Cardiol 2010; 56: 593-607.
26. Lim BK, Shin JO, Lee SC, Kim DK, Choi DJ, Choe SC et al. Long-term cardiac geneexpression using a coxsackieviral vector. J Mol Cell Cardiol 2005; 38: 745-751.
27. Kim YJ, Yun SH, Lim BK, Park KB, Na HN, Jeong SY et al. Systemic analysis of anovel coxsackievirus gene delivery system in a mouse model. J MicrobiolBiotechnol 2009; 19: 307-313.
28. Park JH, Kim DS, Cho YJ, Kim YJ, Jeong SY, Lee SM et al. Attenuation ofcoxsackievirus B3 by VP2 mutation and its application as a vaccine against virusinducedmyocarditis and pancreatitis. Vaccine 2009; 27: 1974-1983.
29. Conaldi PG, Serra C, Mossa A, Falcone V, Basolo F, Camussi G et al. Persistentinfection of human vascular endothelial cells by group B coxsackieviruses. J InfectDis 1997; 175: 693-696.
30. Feuer R, Mena I, Pagarigan R, Slifka MK, Whitton JL. Cell cycle status affectscoxsackievirus replication, persistence, and reactivation in vitro. J Virol 2002; 76:4430-4440.
31. Kim SM, Park JH, Chung SK, Kim JY, Hwang HY, Chung KC et al. Coxsackievirus B3infection induces cyr61 activation via JNK to mediate cell death. J Virol 2004; 78:13479-13488.
32. Knowlton KU, Jeon ES, Berkley N, Wessely R, Huber S. A mutation in thepuff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3. J Virol 1996; 70:7811-7818.
33. Liu P, Aitken K, Kong YY, Opavsky MA, Martino T, Dawood F et al. The tyrosinekinase p56lck is essential in coxsackievirus B3-mediated heart disease. Nat Med2000; 6: 429-434.
34. Forns X, Emerson SU, Tobin GJ, Mushahwar IK, Purcell RH, Bukh J. DNAimmunization of mice and macaques with plasmids encoding hepatitis C virusenvelope E2 protein expressed intracellularly and on the cell surface. Vaccine1999; 17: 1992-2002.
35. Noh YT, Cho JE, Han MG, Lee NY, Kim SY, Chu CS et al. Seroepidemiologicalcharacteristics of haemorrhagic fever with renal syndrome from 1996 to 2005 inKorea. J Bacteriol Virol 2006; 36: 263-269.
36. Huang NF, Niiyama H, Peter C, De A, Natkunam Y, Fleissner F et al. Embryonicstem cell-derived endothelial cells engraft into the ischemic hindlimb and restoreperfusion. Arterioscler Thromb Vasc Biol 2010; 20: 984-991.
37. Kim JY, Cao L, Shvartsman D, Silva EA, Mooney DJ. Targeted delivery ofnanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. NanoLett 2011; 11: 694-700.